Dystroglycan, a ubiquitous membrane-spanning cell adhesion molecule, is a crucial link between the actin cytoskeleton and the extracellular matrix. With a wide expression pattern and multiple interacting proteins, not only is dystroglycan now thought to be important as a structural molecule but also new research has suggested that it has a role in cell signalling, cytoskeleton reorganization and as a potential tumour suppressor.
Introduction
The interaction between a cell and its surroundings is regulated by adhesion molecules that allow the ECM (extracellular matrix) to communicate with the underlying cell cytoskeleton. One such adhesion molecule is dystroglycan, which was first identified in skeletal muscles as a component of a large multimeric protein assembly, the DGC (dystrophin-glycoprotein complex) [1] . The DGC links the actin cytoskeleton to the ECM component laminin. When one or more components of this complex are missing or mutated, this crucial connection is severed, resulting in debilitating neuromuscular diseases.
Dystroglycan is pivotal in maintaining tissue integrity and this has been the focus of much research investigating diseases, such as Duchenne muscular dystrophy. Recently, however, new avenues of research have opened up which implicate dystroglycan in multiple cellular functions in addition to its role as an adhesion molecule. These include early development, cellular signalling and cancer progression. Current understanding of the role of dystroglycan in these areas will be the focus of this mini-review.
Protein structure
Dystroglycan is a heterodimeric glycoprotein that is expressed as a single polypeptide, then post-translationally cleaved into α-and β-subunits. α-Dystroglycan is a heavily glycosylated dumb-bell-shaped peripheral membrane protein. α-Dystroglycan binds the basement membrane component laminin at its N-terminus and β-dystroglycan at its C-terminus. The molecular mass of α-dystroglycan varies between 120 and 180 kDa depending on the tissue, due to differential glycosylation. β-Dystroglycan is a 43 kDa single transmembrane protein that binds α-dystroglycan at its Nterminus and has a cytoplasmic tail that associates with Key words: actin, dystroglycan, extracellular matrix, ezrin, muscular dystrophy, proteolytic processing. Abbreviations used: Cdc42, cell division control 42; DGC, dystrophin-glycoprotein complex; ECM, extracellular matrix; ERK, extracellular-signal-regulated kinase. 1 To whom correspondence should be addressed (email s.winder@sheffield.ac.uk).
dystrophin or utrophin among other proteins (reviewed in [2] ).
Animal models
In contrast with the other components of the DGC, there have been no reported cases of mutations occurring in the human dystroglycan gene, thus suggesting its essential role in the cell. Mutations in glycosyltransferases involved in glycosylation of dystroglycan also give rise to severe muscular dystrophy. The indispensable role of dystroglycan was particularly evident when the dystroglycan knockout mouse was found to be embryonic lethal due to the disruption of the basement membrane at the peri-implantation stage, indicating that dystroglycan is a key player in development [3] . Another study showed that embryoid bodies derived from both developing and mature tissues require dystroglycan for basement membrane formation. A mechanism for this assembly could involve dystroglycan binding to soluble laminin and organizing it on the cell surface [4] . This theory was, however, thrown into controversy by a study using chimaeric mice, whose muscles are deficient in dystroglycan, which were still able to assemble a basement membrane, but nonetheless developed muscular dystrophy and had disrupted neuromuscular junctions [5] . The brain-specific deletion of dystroglycan resulted in brain abnormalities reminiscent of congenital muscular dystrophy [6] . All of this evidence, although conflicting in some areas, implies that dystroglycan is a vital contributor in maintaining tissue integrity and is indispensable for normal development.
Cell biology and signalling
One of the hallmarks of cancer progression is the disruption of the cell-ECM interaction during metastasis. As we have already discussed, dystroglycan is an important adhesion molecule tethering the ECM to the cell cytoskeleton, and when this link is severed it results in severe dystrophic myopathies. The first indication that there is more to dystroglycan than simply a structural adhesion molecule arose with the discovery that β-dystroglycan undergoes proteolytic cleavage by matrix-metalloproteinases to produce an approx. 30 kDa peptide [7] . Interestingly, this peptide was found at an increased level in tumour cells, concurrent with the loss of α-dystroglycan [8] . It was found that the loss of full-length dystroglycan in a breast cancer cell line caused the cells to be impaired in cytoskeletal reorganization, cell polarity and in their response to contact inhibition. Moreover, reexpression of dystroglycan in these cells restored polarity and reduced their invasive capability [9] . Dystroglycan expression levels have also been demonstrated to vary with the cell cycle [10] . Furthermore, tyrosine phosphorylation of β-dystroglycan by c-Src tyrosine kinase induces internalization of dystroglycan into intracellular vesicles, suggesting an endocytic recycling mechanism to control dystroglycan levels at the cell surface [11] . Interestingly, dystroglycan levels were restored in mdx mice, the mouse model of Duchenne muscular dystrophy where dystroglycan is naturally downregulated and treated systemically with a proteosome inhibitor [12] . These findings suggest that dystroglycan expression must be actively regulated for normal function, perhaps to allow the cell to round up prior to cell division. De-regulation of dystroglycan expression levels in cancer cells may contribute to cell metastasis.
The C-terminal domain of β-dystroglycan is a short unfolded cytoplasmic tail that contains binding sites for numerous proteins (reviewed in [2] ). In addition to dystrophin and utrophin, β-dystroglycan binds several signalling molecules. One example of β-dystroglycan modulating signal transduction is its association with ERK (extracellular-signal-related kinase) and its upstream MAPK (mitogen-activated protein kinase) kinase. The role of dystroglycan may be to act as a protein scaffold that sequesters these proteins in separate cellular locations to regulate their adhesion-dependent activation [13] . When dystroglycan is overexpressed in fibroblasts, it results in an increase in actin protrusions such as microvilli and filopodia. β-Dystroglycan cytoplasmic tail has also been shown to bind and bundle filamentous actin directly, independently of utrophin [14] . In addition, we have shown that β-dystroglycan binds the cytoskeletal adaptor protein, ezrin, and uses this partnership to modulate actin reorganization in fibroblasts via the Cdc42 pathway [15] . Our current data suggest that dystroglycan and ezrin form a complex with a RhoGEF (guanine nucleotide-exchange factor), which may be responsible for activating Cdc42 in a localized manner and thus cause the filopodia phenotype (S.J. Winder and C.L. Batchelor, unpublished work).
Summary
Dystroglycan has a clear role in maintaining sarcolemmal integrity in skeletal muscles. This is probably due to its role as a physical link between the ECM and the cytoskeleton. However, emerging evidence suggests that dystroglycan has a more active function in the transduction of a variety of signalling pathways. Further research into the role of dystroglycan in these signalling pathways will not only provide greater insight into a number of fundamental processes, but also help us to understand how they are de-regulated in diseases such as muscular dystrophy and cancer.
